Takeda  FY Results (April 1, 2007 – March 31, 2008)

FY Revenues: $13.9 billion (+5%)

FY Earnings: $3.6 billion (+6%)

Comments: FY growth was driven by Actos sales of $4.0 billion (+18%) and Candesartan/Blopress sales of $2.2 billion (+8%). Lansoprazole sales were $1.5 billion (-1%). Leuprorelin sales were $1.3 billion (-3%). Operating income was $4.1 billion (-8%). R&D expenses were up 43% due to enhancement of R&D activities, in-licensing and alliance activities, including the termination of a license agreement with Amgen.